Sudan Virus Vaccine Safety Study for Healthy Adults
Part of Infections clinical trials.
This study tests a new experimental vaccine designed to protect against Sudan virus, a rare but serious disease. Researchers will check if the vaccine is safe and helps your immune system fight off the virus.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 50 years old and in good overall health
- You are willing to use condoms consistently for 3 months after receiving the vaccine
- If you can become pregnant, you must use reliable birth control for 2 weeks before and 3 months after the vaccine
- You have not received certain vaccines (like live flu vaccine) within the past 2–4 weeks
- You do not have HIV, hepatitis B or C, or other serious infections
- You are willing to take an HIV test and receive counseling about sexual health
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new vaccine to protect against Marburg virus, a rare but serious infection. The vaccine uses a weakened virus to teach your body to fight the Marburg virus, and researchers are checking if it is safe and how well it works.
This study tests a new vaccine, V4020, that may help protect against Venezuelan equine encephalitis (VEE), a rare but serious virus spread by mosquitoes. It is the first step in humans to see if it is safe and how the body responds.
This study tests how safe a Rift Valley fever (RVF) vaccine is and how strongly it triggers the body’s immune response. You may be eligible if you are at risk of RVF exposure and your blood test shows you don’t already have strong protection.
This study tests a new Ebola vaccine to see if it is safe and how well it works. Healthy volunteers receive the vaccine and are monitored for side effects and immune response.
This study tests an experimental vaccine to see if it is safe for healthy adults. The vaccine is made with mRNA technology and aims to protect against RSV, a common respiratory virus.
This trial tests an experimental vaccine for respiratory syncytial virus (RSV), a common virus that can cause serious lung infections, especially in older adults. The study checks if the vaccine is safe and how the body responds to it.
Hear when a new Sudan Virus Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.